Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438320 · ClinicalTrials.gov registry record · Phase 1
Q-Trial in Patients With Hepatitis C
A Phase 1 study of Chronic Hepatitis C, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01438320: Completed Phase 1 study of Chronic Hepatitis C, sponsored by University of California, Los Angeles.
NCT01438320 is a Phase 1 study of Chronic Hepatitis C that has completed, run by University of California, Los Angeles. The registered enrollment target is 34 participants, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01438320, a Phase 1 study of Chronic Hepatitis C, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to translate laboratory findings that Quercetin, a bioflavonoid, is safe and has antiviral activity in people with hepatitis C.
Primary Outcome
Primary outcome for the study will be safety. The investigators will track various laboratory parameters including viral loads and see patients every 2 weeks during our drug phase which is 28 days. After that follow patients every month to see how long antiviral activity will persist if we do see a positive outcome.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Quercetin
Study Locations (1)
California
- UCLA Jonsson Comprehensive Cancer Center. Factor Building - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT01438320 record still lists
NCT01438320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Quercetin is the first listed.
NCT01438320 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01438320 about?
NCT01438320 is a clinical study titled "Q-Trial in Patients With Hepatitis C". The goal of this study is to translate laboratory findings that Quercetin, a bioflavonoid, is safe and has antiviral activity in people with hepatitis C.
What is the current status of trial NCT01438320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2011-07. Estimated completion is 2014-06.
What conditions does trial NCT01438320 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT01438320?
The interventions under investigation include: Quercetin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01438320?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01438320 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01438320's enrollment target sits among peer trials
34 12th of 16 higher than 5 of 16 other Chronic Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
COMPLETED · Phase 1
-
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
COMPLETED · Phase 1
-
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
COMPLETED · Phase 1
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia